Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome
- Authors: Uspenskaya Y.B1, Kuznetsova I.V1, Vedzizheva E.R1
-
Affiliations:
- I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 18, No 6 (2016)
- Pages: 52-58
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94496
- ID: 94496
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Yu. B Uspenskaya
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Email: jusp@mail.ru
канд. мед. наук, вед. науч. сотр. научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
I. V Kuznetsova
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationд-р мед. наук, проф., гл. науч. сотр. научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
E. R Vedzizheva
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationаспирант научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
References
- Буеверов А.О. Возможности лечения лекарственных поражений печени в условиях необходимости приема гепатотоксичных препаратов. Лечащий врач. 2009; 2: 40-2.
- Никитин И.Г. Скрининговая программа по выявлению распространенности неалкогольной жировой болезни печени и определению факторов риска развития заболевания. Рос. мед. вести. 2010; 4 (1): 41-6.
- Руководство по амбулаторно - поликлинической помощи в акушерстве и гинекологии. Под ред. В.Е.Радзинского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2014.
- Руководство по репродуктивной медицине. Под ред. Б.Карра, Р.Блэкуэлла, Р.Азиза. Пер. с англ. М.: Практика, 2015.
- Abdelmalek M.F, Diehl A.M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007; 91: 1125-49.
- Adams L.A, Lymp J.F, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population - based cohort study. Gastroenterology 2005; 129: 113-21.
- Agacayak E, Tunc S.Y, Sak S et al. Levels of Neopterin and other Inflammatory Markers in Obese and Non-Obese Patients with Polycystic Ovary Syndrome. Med Sci Monit 2015; 21: 2446-55.
- Alvarez-Blasco F, Botella-Carretero J.I, San Millán J.L, Escobar-Morreale H.F. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166: 2081-6.
- American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. National Guideline Clearinghouse. Available at http://guideline.gov/summary/summary.aspx?doc_id=7108. Accessed: August 28, 2009.
- Angulo P, Alba L.M, Petrovic L.M et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41 (6): 943-9.
- Awartani K.A, Cheung A.P. Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can 2002; 24 (5): 393-401.
- Azziz R, Woods K.S, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-9.
- Azziz R, Dumesic D.A, Goodarzi M.O. Polycystic ovary syndrome: an ancient disorder? Fertil Steril 2011; 95: 1544-8.
- Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001; 80: 230-9.
- Baranova A, Tran T.P, Afendy A et al. Molecular signature of adipose tissue in patients with both nonalcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med 2013; 11: 133.
- Baranova A, Tran T.P, Birerdinc A, Younossi Z.M. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non - alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 801-4.
- Barber T.M, Franks S. Genetics of polycystic ovary syndrome. Front Horm Res 2013; 40: 28-39.
- Brower M.A, Jones M.R, Rotter J.I et al. Further investigation in Europeans of susceptibility variants for polycystic ovary syndrome discovered in genome - wide association studies of Chinese individuals. J Clin Endocrinol Metab 2015; 100: 182-6.
- Brzozowska M.M, Ostapowicz G, Weltman M.D. An association between non - alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009; 24: 243-7.
- Bugianesi E, Gastaldelli A, Vanni E et al. Insulin resistance in non - diabetic patients with non - alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48 (4): 634-42.
- Cadranel J.F, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
- Cankaya S, Demir B, Aksakal S.E et al. Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome. Fertil Steril 2014; 102: 826-30.
- Cerda C, Perez-Ayuso R.M, Riquelme A et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47 (3): 412-7.
- Chalasani N, Younossi Z, Lavine J.E et al. The diagnosis and management of non - alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
- Chang R.J, Nakamura R.M, Judd H.L, Kaplan S.A. Insulinresistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356-9.
- Ciotta L, Pagano I, Stracquadanio M, Formuso C. Polycystic ovarian syndrome incidence in young women with non - alcoholic fatty liver disease. Minerva Ginecol 2011; 63: 429-37.
- Cusi K, Charlton M, Sanyal A.J. The diagnosis and management of non - alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
- Cussons A.J, Watts G.F, Mori T.A, Stuckey B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842-8.
- Diamanti-Kandarakis E, Christakou C.D. Insulin Resistance in PCOS. Springer, 2009.
- Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006; 30 (1): 13-7.
- Dunaif A, Graf M, Mandeli J et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65: 499-507.
- Dunaif A, Segal K.R, Shelley D.R et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-66.
- Dunaif A. Drug insight: insulin - sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nat Clin Pract Endocrinol Metab 2008; 4: 272-83.
- Economou F, Xyrafis X, Livadas S et al. In overweight/obese but not in normal - weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009; 8: 199-206.
- El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 109: 239-41.
- Feldstein A.E, Wieckowska A, Lopez A.R et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.
- Gambarin-Gelwan M, Kinkhabwala S.V, Schiano T.D et al. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007; 5: 496-501.
- Gangale M.F, Miele L, Lanzone A et al. Long - term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2011; 75: 520-7.
- Gao T, Wu L, Chang F, Cao G. Low circulating ghrelin levels in women with polycystic ovary syndrome: a systematic review and meta - analysis. Endocr J 2016; 63 (1): 93-100.
- Gauna C, van der Lely A.J. Somatostatin, cortistatin, ghrelin and glucose metabolism. J Endocrinol Invest 2005; 28: 127-31.
- Goldman M.H, Scheraldi C.A, Soule W.C. Ovarian hyperthecosis associated with fatty liver disease. Am J Obstet Gynecol 1987; 156: 1239-40.
- Gomez-Meade C.A, Lopez-Mitnik G, Messiah S.E et al. Cardiometabolic health among gastric bypass surgery patients with polycystic ovarian syndrome. World J Diabetes 2013; 4: 64-9.
- Gonzalez F, Sia C.L, Bearson D.M, Blair H.E. Hyperandrogenism induces a proinflammatory TNFa response to glucose ingestion in a receptor - dependent fashion. Endocrine J Clin Endocrinol Metab 2016; 51: 211-21.
- Goodman N.F, Cobin R.H, Futterweit W et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 1. Endocr Pract 2015; 21 (11): 1291-300.
- Goverde A.J, van Koert A.J, Eijkemans M.J et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 2009; 24: 710-7.
- Harrison S.A, Torgerson S, Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-7.
- Jamali R. Non - Alcoholic Fatty Liver Disease. Walter Siegenthaler, 2013.
- Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
- Kauffman R.P, Baker T.E, Baker V et al. Endocrine factors associated with non - alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 2010; 26: 39-46.
- Kojima M, Hosoda H, Date Y et al. Ghrelin is a growth - hormone - releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
- Kola B, Hubina E, Tucci S.A et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005; 280: 25196-201.
- Komarowska H, Wasko R, Iwanik K et al. Ghrelin ovarian cell expression in patients with polycystic ovary syndrome: animmunohistochemical evaluation. Horm Metab Res 2006; 38: 783-8.
- Lee Y.H, Pratley R.E. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70-5.
- Legro R.S, Arslanian S.A, Ehrmann D.A et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-92.
- Lerchbaum E, Gruber H.J, Schwetz V et al. Fatty liver index in polycystic ovary syndrome. Eur J Endocrinol 2011; 165: 935-43.
- Li Y, Hai J, Li L et al. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non - alcoholic fatty liver disease development. Endocrine 2013; 43: 376-86.
- Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6 (4): 236-47.
- Macut D, Tziomalos K, Božić-Antić I et al. Non - alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 2016. pii: dew076.
- Mao Y, Cheng J, Yu F et al. Ghrelin Attenuated Lipotoxicity via Autophagy Induction and Nuclear Factor-κB Inhibition. Cell Physiol Biochem 2015; 37 (2): 563-76.
- March W.A, Moore V.M, Willson K.J et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-51.
- Marchesini G, Brizi M, Morselli-Labate A.M et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107 (5): 450-5.
- Mitkov M, Pehlivanov B, Orbetzova M. Serum ghrelin level in women with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters. Gynecol Endocrinol 2008; 24: 625-30.
- Murata M, Okimura Y, Iida K et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002; 277: 5667-74.
- Myers R.P, Fong A, Shaheen A.A. Utilization rates, complications and costs of percutaneous liver biopsy: a population - based study including 4275 biopsies. Liver Int 2008; 28: 705-12.
- Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl - ghrelin and it association with non - alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord 2015; 14: 44.
- Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
- Nehir Aytan A, Bastu E, Demiral I et al. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol 2016 Mar 7: 1-5.
- O’Reilly M.W, Taylor A.E, Crabtree N.J et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014; 99: 1027-36.
- Ozturk Z.A, Kadayifci A. Insulin sensitizers for the treatment of nonalcoholic fatty liver disease. World J Hepatol 2014; 6 (4): 199-206.
- Panidis D, Tziomalos K, Misichronis G et al. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2012; 27: 541-9.
- Parker H.M, Johnson N.A, Burdon C.A et al. Omega-3 supplementation and non - alcoholic fatty liver disease: a systematic review and meta - analysis. J Hepatol 2012; 56: 944-51.
- Pasquali R, Casimirri F, Venturoli S et al. Body fat distribution has weight - independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 43: 706-13.
- Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine minotransferase levels. Ann Intern Med 2002; 137: 1-10.
- Preiss D, Sattar N, Harborne L et al. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract 2008; 62: 1337-43.
- Qu Z, Zhu Y, Jiang J et al. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. Iran J Reprod Med 2013; 11 (9): 725-32.
- Ramezani-Binabaj M, Motalebi M, Karimi-Sari H et al. Are women with polycystic ovarian syndrome at a high risk of non - alcoholic Fatty liver disease; a meta - analysis. Hepat Mon 2014; 14 (11): e23235.
- Randeva H.S, Tan B.K, Weickert M.O et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33: 812-41.
- Rodríguez A, Gómez-Ambrosi J, Catalán V et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 2009; 33: 541-52.
- Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355-65.
- Rosenfield R.L. Clinical review: adolescent anovulation: maturational mechanisms and implications. J Clin Endocrinol Metab 2013; 98: 3572-83.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteriaand long - term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
- Saadeh S, Younossi Z.M, Remer E.M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123 (3): 745-50.
- Schwimmer J.B, Khorram O, Chiu V, Schwimmer W.B. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 494-7.
- Setji T.L, Holland N.D, Sanders L.L et al. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1741-7.
- Siegelman E.S, Rosen M.A. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21 (1): 71-80.
- Sirmans S.M, Pate K.A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13.
- Syn W.K, Choi S.S, Diehl A.M. Apoptosis and cytokines in non - alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 565-80.
- Tan S, Bechmann L.P, Benson S et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 343-8.
- Targher G, Bertolini L, Scala L et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-3.
- Targher G, Solagna E, Tosi F et al. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest 2009; 32: 695-700.
- Thoma C, Day C.P, Trenell M.I. Lifestyle interventions for the treatment of non - alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-66.
- Tong J, Prigeon R.L, Davis H.W et al. Ghrelin suppresses glucose - stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010; 59: 2145-51.
- Toulis K.A, Goulis D.G, Farmakiotis D et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta - analysis. Hum Reprod Update 2009; 15 (3): 297-307.
- Tziomalos K, Athyros V.G, Karagiannis A. Non - alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 2012; 10: 162-72.
- Utzschneider K.M, Kahn S.E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91 (12): 4753-61.
- Van der Lely A.J, Tschop M, Heiman M.L, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-57.
- Vassilatou E, Lafoyianni S, Vryonidou A et al. Increased androgen bioavailability is associated with non - alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25: 212-20.
- Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014; 20 (26): 8351-63.
- Vernon G, Baranova A, Younossi Z.M. Systematic review: the epidemiology and natural history of non - alcoholic fatty liver disease and non - alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
- Wieckowska A, Mc Cullough A.J, Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-9.
- Younossi Z.M, Reyes M.J, Mishra A et al. Systematic review with meta - analysis: non - alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39: 3-14.
- Zueff L.F, Martins W.P, Vieira C.S, Ferriani R.A. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 2012; 39 (3): 341-7.